Skip to main
COLL

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical Inc. demonstrates a robust financial outlook, driven by significant growth in its product Jornay, which achieved $42 million in revenue, reflecting a 19% year-over-year increase and surpassing market expectations. The company is implementing an expanded sales force, increasing from 55 to 180 representatives, which is projected to enhance education and awareness among healthcare providers and patients, further positioning Jornay for sustained market share growth. With a consistent trend of increasing prescriptions and a solid foundation in its abuse-deterrent technology, Collegium is well-positioned to capitalize on the safer opioid theme, reinforcing its potential for continued top-line performance through 2026 and beyond.

Bears say

Collegium Pharmaceutical Inc. faces a negative outlook due to several financial risks, primarily stemming from lower projected sales for key products such as Xtampza ER and Belbuca, with 2026 guidance indicating a decline in pain portfolio sales to approximately $620 million compared to $632 million in 2025. Additionally, there are significant concerns regarding earlier generic competition for these products and the potential impact on net profits from third-party generics, which could further dampen revenue expectations. Execution risks linked to commercialization and the reliability of third-party suppliers also pose serious challenges that could affect the overall profitability of Collegium’s offerings.

Collegium Pharmaceutical (COLL) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Buy based on their latest research and market trends.

According to 5 analysts, Collegium Pharmaceutical (COLL) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.